Best of ASCO - 2014 Annual Meeting



Attend this session at the
2017 ASCO Annual Meeting!

Session: Developmental Therapeutics—Immunotherapy

Type: Poster Session

Time: Monday June 5, 8:00 AM to 11:30 AM

Location: Hall A

Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.

Cellular Immunotherapy

Developmental Therapeutics—Immunotherapy

2017 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Session (Board #140)

J Clin Oncol 35, 2017 (suppl; abstr 3045)

Author(s): Amod Sarnaik, Harriet M. Kluger, Jason Alan Chesney, Jyothi Sethuraman, Anandharamen Veerapathran, Michelle Simpson-Abelson, Michael T. Lotze, Bente Larsen, Steven A. Fischkoff, Sam Suzuki, Lei Wang, Mariam Mirgoli, Maria Fardis, Brendan D. Curti; Moffitt Cancer Center, Tampa, FL; Yale School of Medicine, New Haven, CT; University of Louisville, Louisville, KY; Lion Biotechnologies, Inc., Tampa, FL; Lion Biotechnologies, Inc., New York, NY; Lion Biotechnologies, Inc., San Carlos, CA; Earl A. Chiles Research Institute, Portland, OR

Abstract Disclosures


Background: Adoptive cell therapy with TIL involves collection of autologous lymphocytes from the tumor via surgical resection, ex vivo expansion of TIL, lymphodepletion of the patient prior to infusion of TIL using Fludarabine and Cyclophosphamide, followed by infusion of TIL. Up to 6 doses of IL-2 (600,000 IU/kg) is administered to support multiplication of TIL and engraftment. Here, we present the preliminary results from an ongoing, multi-site Phase 2 study of TIL for advanced metastatic melanoma. Methods: Patients with advanced metastatic melanoma who have failed at least one prior systemic therapy were enrolled. Primary objective of the study was to characterize safety profile of LN-144. At baseline, patients had a median age of 56 (41-72) years; 44% were ≥ 60 years old. Median sum of tumor diameters for the target lesions was 10.4 cm, and median of 3 prior therapies. All enlisted patients had prior anti-PD1 as well as anti-CTLA4 and 67% had received ≥ 3 prior therapies. Responses were assessed by RECIST 1.1. TIL products were centrally manufactured. No complications arose from shipment of tumors or TIL. Results: Results are presented through 31 Jan 2017 for the first 9 infused patients evaluable by two assessments. Eight of 9 patients received all 6 doses of IL-2 per protocol. The most common (≥3 patients) non-hematologic grade 3-4 TEAE was hypophosphatemia. No neurotoxicity of grade ≥ 3 was reported. There were no deaths or discontinuations due to SAEs related to study treatment. ORR was 33% (CR = 11%, PR = 22%, SD = 22%, PD = 33%, NE = 11%). Mean time to best response was 3.0 months and median duration of follow up was 3.6 months (1.1+, 12.1). Responses were observed in patients with tumors carrying wild type or BRAF mutations. All patients demonstrated persistence of TIL on day 14 post-infusion. Conclusions: Cell therapy with TIL is an effective treatment with acceptable safety profile for advanced metastatic melanoma patients who are refractory to anti-PD1. TIL products can be centrally manufactured for broad clinical application. This study will be expanded to enroll patients with a shorter manufacturing process as well as offering retreatment for study patients. Clinical trial information: NCT02360579

Other Abstracts in this Sub-Category:


1. The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).

Meeting: 2017 ASCO Annual Meeting Abstract No: 103 First Author: Shannon L. Maude
Category: Developmental Therapeutics—Immunotherapy - Cellular Immunotherapy


2. Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043).

Meeting: 2017 ASCO Annual Meeting Abstract No: 3000 First Author: Crystal Mackall
Category: Developmental Therapeutics—Immunotherapy - Cellular Immunotherapy


3. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

Meeting: 2017 ASCO Annual Meeting Abstract No: LBA3001 First Author: Frank (Xiaohu) Fan
Category: Developmental Therapeutics—Immunotherapy - Cellular Immunotherapy